Vision RT & DoseOptics Sign Long Term Partnership to Advance Cherenkov Imaging

Following several years of collaboration, Vision RT Limited, the leading provider of SGRT solutions, has announced a strategic partnership with DoseOptics LLC, the pioneering innovator of Cherenkov imaging through which a fully integrated and unique offering combining the two technologies will be provided.

Working together for the past 5 years, the two companies have developed DoseRT™ powered by BeamSite® – a radiation therapy monitoring solution that uses Cherenkov imaging to reveal and visualize the radiation dose as it is delivered, working alongside AlignRT® Horizon cameras, which monitor the patient’s position.

DoseRT has been through extensive clinical testing and is in the final stages of its formal development. It is scheduled to launch commercially in 2024.

The landmark agreement announced today marks a strengthening of the long-term commitment between the two companies. The partnership brings together efforts of DoseOptics’ strengths in Cherenkov imaging research and development with Vision RT’s expertise in SGRT, product execution and global sales reach.

“We are very excited to be partnering with DoseOptics on this groundbreaking new technology,” said Norman Smith, founder, and CEO of Vision RT. “Our joint efforts have resulted in a truly innovative solution that will change the landscape of visualizing radiation therapy for patients in real-time. We look forward to the continued success of this partnership and to providing our customers unparalleled treatment quality and safety assurance tools”.

Vision RT will continue to collaborate with DoseOptics strengthening Vision RT’s range of solutions, using surface guidance to improve the safety, effectiveness and efficiency of the entire radiation therapy workflow.

William Ware, co-founder and CEO of DoseOptics, comments, “We are proud to partner with Vision RT, the leader in SGRT, and believe that, together, we can make the marriage of Cherenkov imaging and SGRT, combining information about patient position and beam dose, standard of care.”

—

About Vision RT

• Vision RT defines the standard of care in Surface Guided Radiation Therapy. We provide superior solutions for the radiotherapy market, with more than 2,700 systems in active clinical use in many of the leading treatment centers in the world, including all 15 of the top 15 US News “Best Hospitals for Cancer”.  We continue to innovate in the radiation oncology space with our MapRT clearance mapping (pending approval) and InBore SGRT solutions. We are committed to making SGRT the standard of care for all patients, worldwide.

About DoseOptics LLC

• DoseOptics makes BeamSite®, the world’s first Cherenkov imaging system for radiotherapy, enabling clinical teams to simply see radiotherapy treatments as they happen, in real-time, on every fraction of every patient. BeamSite provides the clinical team with an intuitive, visual means of treatment verification for an unprecedented level of safety and quality. BeamSite is FDA cleared and currently available for radiotherapy clinics in the United States.

For more information about DoseRT, visit https://visionrt.com/DoseRT